TITLE

S*BIO/UNIVERSITY OF SINGAPORE PARTNER ON TUMOR BIOAMARKER

PUB. DATE
July 2007
SOURCE
Worldwide Biotech;Jul2007, Vol. 19 Issue 7, p7
SOURCE TYPE
Trade Publication
DOC. TYPE
Article
ABSTRACT
The article focuses on the two-year research partnership forged by S*BIO Pte Ltd. with the National University Hospital-National University of Singapore Tissue Repository (NUH-NUS TR). The partnership is aimed at conducting biomarker research and at evaluating the responsiveness of tumors to the proprietary anti-cancer compounds of S*BIO. Information on the NUH-NUS TR is outlined.
ACCESSION #
25547359

 

Related Articles

  • Singapore's S*BIO Adds $26M for Phase II Studies in Cancer. Hollingsworth, Catherine // BioWorld Today;10/21/2008, Vol. 19 Issue 205, p1 

    The article reports that S*BIO Pte. Ltd. has raised $26 million to fund phase II trials for the SB939 and SB1518 cancer drugs in 2008. The financing was led by Bio*One Capital, a member of the Singapore Economic Development Authority and Aravis Venture. In a statement, chief executive Jan Anders...

  • Correction.  // BioWorld Today;4/6/2007, Vol. 18 Issue 67, p2 

    A correction to the misidentification of the location of the headquarters of the company S*BIO Pte. Ltd. that was published in the April 4, 2007 issue is presented.

  • S*BIO INITIATES CLINICAL TRIAL OF NOVEL ANTI-CANCER DRUG.  // Worldwide Biotech;Aug2007, Vol. 19 Issue 8, p1 

    The article reports that the clinical trial of the novel anti-cancer drug was initiated by the S*BIO Pte Ltd. in Singapore. The SB939 is a histone deacetylase (HDAC) inhibitor which is a targeted anti-cancer therapeutics. The SB939 Phase I trial was conducted to determine its pharmacokinetic and...

  • CLINIC ROUNDUP.  // BioWorld Today;9/19/2008, Vol. 19 Issue 183, p7 

    This section offers news briefs on the pharmaceutical industry. Avigen Inc. has completed the double-blind portion of its Phase IIb trial for AV650 used in the treatment of spasticity linked to multiple sclerosis. Positive results were reported by Incyte Corp. from Phase IIa trials of topical...

  • Wilex, Prometheus in Potential $145M Deal for Rencarex. Sheridan, Cormac // BioWorld International;5/11/2011, Vol. 16 Issue 19, p1 

    The article reports on the partnership between Wilex AG and Prometheus Laboratories for Rencarex (girentuximab), a Phase III anticancer antibody, in 2011. Under the agreement, Wilex AG secures 19 million U.S. dollars up front, royalties on net U.S. sales, and an option to acquire European...

  • Agilent Technologies and National University of Singapore Sign Research Collaboration Agreement for Lipidomics Research.  // Biomedical Market Newsletter;4/30/2011, p131 

    The article reports on the partnership of Agilent Technologies Inc. and the National University of Singapore (NUS) to develop expertise and knowledge in the field of analytical lipidomics. It states that the partnership aims to develop workflow solutions to allow researchers to more accurately...

  • Preclinical antitumour activity of F 11782, a novel dual catalytic inhibitor of topoisomerases. Kruczynski, A; Etiévant, C; Perrin, D; Imbert, T; Colpaert, F; Hill, B T // British Journal of Cancer;12/1/2000, Vol. 83 Issue 11, p1516 

    F 11782 is a novel inhibitor of topoisomerases I and II, with an original mechanism of action (Perrin et al, 2000). This study, aimed to define its anticancer efficacy against a series of murine and human tumour models, has provided evidence of major antitumour activity for F 11782. This was...

  • Anti-tumour activity and toxicity of the new prodrug 9-aminocamptothecin glucuronide (9ACG) in mice. Prijovich, Z.M.; Chen, B.-M.; Leu, Y.-L.; Chern, J.-W.; Roffler, S.R. // British Journal of Cancer;5/20/2002, Vol. 86 Issue 10, p1634 

    Cancer chemotherapy is limited by the modest therapeutic index of most antineoplastic drugs. Some glucuronide prodrugs may display selective anti-tumour activity against tumours that accumulate β-glucuronidase. We examined the toxicity and anti-tumour activity of 9-aminocamptothecin...

  • Pharmacological Strategies to Increase the Antitumor Activity of Methylating Agents. Tentori, Lucio; Graziani, Grazia // Current Medicinal Chemistry;Jul2002, Vol. 9 Issue 13, p1285 

    Among methylating agents of clinical interest, temozolomide is a novel antitumor compound that has raised particular interest due to its acceptable safety profile and activity against tumors poorly responsive to conventional chemotherapy, such as malignant glioma and metastatic melanoma....

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics